Cartography Biosciences, a precision oncology company developing next-generation T-cell engaging antibody therapeutics, announced it has closed a $67 million Series B financing to accelerate its differentiated pipeline toward the clinic. The round was led by Pfizer Ventures, with participation from new investors LG Corp, Amgen Ventures, Finchley H.V., Global BioAccess Fund, and Lotte Holdings CVC, alongside existing backers Andreessen Horowitz (a16z) Bio + Health, 8VC, Wing Venture Capital, Catalio Capital Management, AME Cloud Ventures, ARTIS Ventures, and Gaingels.
The proceeds will primarily fund CBI-1214, Cartography’s lead T-cell engager targeting LY6G6D—a novel tumor antigen associated with colorectal cancer (CRC)—as it advances toward an Investigational New Drug (IND) application later this year and first-in-human clinical trials in early 2026. The financing will also support the continued expansion of the company’s pipeline derived from its ATLAS and SUMMIT discovery platforms, which leverage high-dimensional data to identify highly specific tumor antigens and antigen pairs.
As part of the investment, Michael Baran, MBA, Ph.D., Partner at Pfizer Ventures, has joined Cartography’s Board of Directors, and Troy E. Wilson, Ph.D., J.D., has been elected Chairman of the Board.
Cartography’s flagship program, CBI-1214, is designed to target LY6G6D, a highly selective tumor antigen expressed in microsatellite stable (MSS) and microsatellite instability-low (MSI-L) subtypes of CRC—forms that account for the majority of colorectal cancer patients and for which few targeted therapies exist. The engineered T-cell engager features advanced protein design intended to enhance tumor selectivity and anti-tumor potency while minimizing off-target effects.
By targeting tumor-specific surface antigens with minimal expression in healthy tissue, Cartography seeks to overcome the limitations of current immunotherapies and deliver targeted treatments to patient populations that checkpoint inhibitors and conventional antibody therapies have historically underserved.
KEY QUOTES:
“Cartography is uniquely positioned to lead the potential next generation of T-cell engagers with a novel late preclinical program for colorectal cancer. With a strong discovery platform and a growing pipeline, Cartography is quickly emerging as a leader in antibody therapeutics, and Pfizer Ventures is excited to support their progress in bringing potential new treatments to patients.”
Michael Baran, MBA, Ph.D., Partner, Pfizer Ventures
“Combining insights from thousands of patient tissue samples, our ATLAS and SUMMIT platforms have identified several novel targets and target pairs that we have engineered new T-cell engagers against. CBI-1214, our first announced program, has the potential to be a first- and best-in-class molecule targeting CRC and positions Cartography as an emerging leader in new targeted therapies. We are grateful for the support of Pfizer Ventures and a world-class roster of strategic and financial investors as we move forward with CBI-1214.”
Kevin Parker, Ph.D., Chief Executive Officer, Cartography Biosciences
